A recent study evaluated the long-term effects of sotatercept, a biologic targeting activin signaling, on adults with pulmonary arterial hypertension (PAH). Over a year, the treatment showed sustained improvements in exercise capacity and cardiac biomarkers among participants, alongside a consistent safety profile. Data from 426 patients indicated significant increases in the 6-minute walk distance and a reduction in NT-proBNP levels. Despite adverse events, most were mild, and the ongoing study will extend its follow-up for further insights.

Source: ERS Publications